期刊
INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 99, 期 3, 页码 272-278出版社
SPRINGER JAPAN KK
DOI: 10.1007/s12185-014-1503-4
关键词
AML; Midostaurin; ATRA; Phase I; Targeted therapy; CLAG
类别
资金
- Novartis
We conducted a phase I study using midostaurin (25 or 50 mg orally twice daily), all-trans retinoic acid (ATRA) and CLAG chemotherapy to target multiple pathways in relapsed/refractory AML. 10 patients received the combination and no dose-limiting toxicities were observed. Two patients (22 %) achieved complete remission and 1 patient (11 %) achieved complete remission with incomplete count recovery. Pharmacokinetic data showed that the 25 mg dosing of midostaurin achieved therapeutic levels with no significant interaction between midostaurin and ATRA. With evidence of activity of ATRA in NPM1-mutated AML and midostaurin in FLT3-ITD AML, this combination warrants further investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据